Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Tyligand Bioscience / Equity Capital Markets

<ul>
<li>Tyligand Bioscience, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC is the sole sponsor.</li>
<li>In this note, we look at the company's one late-stage core product TSN1611.</li>
<li>We also look at the company's pre-IPO investors and management team.</li>
</ul>


Tyligand Bioscience, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC is the sole sponsor.
In this note, we look at the company's one late-stage core product TSN1611.
We also look at the company's pre-IPO investors and management team.


Tyligand Bioscience (泰励生物) Pre-IPO: Late Entrant to the KRAS G12D Target

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tyligand Bioscience (TLG HK)

Tyligand Bioscience (泰励生物) Pre-IPO: Late Entrant to the KRAS G12D Target

China biotech Tyligand Bioscience aims to raise $100 million through Hong Kong listing with CITIC as sole sponsor. We look at its late-stage core...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Tyligand Bioscience (泰励生物) Pre-IPO: Late Entrant to the KRAS G12D Target

​China biotech Tyligand Bioscience aims to raise $100 million through Hong Kong listing with CITIC as sole sponsor. We look at its late-stage core...

Ke Yan, CFA, FRM

China biotech Tyligand Bioscience aims to raise $100 million through Hong Kong listing with CITIC as sole sponsor. We look at its late-stage core...